AI-Powered News AnalysisCompare coverage across the political spectrum
Back to Dashboard
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug - Reuters

US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug - Reuters

US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug Reuters

May 14, 2026 at 06:22 PM Original source
7 agencies covered this story

Coverage by Political Leaning

See how different sides of the spectrum reported this story

Left
0 articles
No coverage
Lean Left
1 articles
Center
6 articles
Lean Right
0 articles
No coverage
Right
0 articles
No coverage

Key People

No people linked to this story

All Coverage

US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug - Reuters
Reutersvia rss

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNV2FXR19tUWxiQ2RMdWp5SHJZUFlpSEUtamdIMXdReTd4UzV0Zm0xODZCeGE0bEt4Nmd2MVV6akl6OGtQdVVwNTlEczIwcHVhVGNHVVplMUROQUZoUTFKcHI1ajY1Y3UydGZsZGtsM3duc3BDeDlWQl9LaGtaNFgtMk1LbWcwTXlkVEpIOEMtTGppOTFJMVBPX3RnS0xOaFR1ekhyWlhHMTlLYWplclF4LTFvd3NFWC02V2NrOE9VQzNtX0R0RmJz?oc=5" target="_blank">US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

100%
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug
AOLvia ai

U.S. cancer centers are urgently enrolling patients in an early access program for Revolution Medicines' experimental drug daraxonrasib, following its FDA-approved expanded access program on May 1, 2026.

80%
Medscapevia ai

Medscape reports on the challenges faced by U.S. cancer clinics in accessing Revolution Medicines' experimental drug daraxonrasib, highlighting the FDA's recent approval for expanded access.

80%
Medscapevia ai

Medscape discusses the urgency among U.S. cancer clinics to provide patients with access to Revolution Medicines' experimental drug daraxonrasib, following the FDA's approval for expanded access.

80%
Medscapevia ai

Medscape reports on the challenges faced by U.S. cancer clinics in accessing Revolution Medicines' experimental drug daraxonrasib, following the FDA's recent approval for expanded access.

80%
Medscapevia ai

Medscape discusses the urgency among U.S. cancer clinics to provide patients with access to Revolution Medicines' experimental drug daraxonrasib, following the FDA's approval for expanded access.

80%
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug
Yahoo News Malaysiavia ai

Yahoo News Malaysia reports on the challenges faced by U.S. cancer clinics in accessing Revolution Medicines' experimental drug daraxonrasib, following the FDA's recent approval for expanded access.

80%